Last reviewed · How we verify

Kuvan — Competitive Intelligence Brief

Kuvan (SAPROPTERIN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phenylalanine Hydroxylase Activator. Area: Oncology.

marketed Phenylalanine Hydroxylase Activator Nitric oxide synthase, brain Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Kuvan (SAPROPTERIN) — BioMarin. Kuvan works by activating the enzyme Phenylalanine Hydroxylase to break down phenylalanine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Kuvan TARGET SAPROPTERIN BioMarin marketed Phenylalanine Hydroxylase Activator Nitric oxide synthase, brain 2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phenylalanine Hydroxylase Activator class)

  1. BioMarin · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kuvan — Competitive Intelligence Brief. https://druglandscape.com/ci/sapropterin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: